/CAI
Caris Life Sciences, Inc.
CAI • NASDAQCAI • NASDAQ • Healthcare
$18.14+2.54%+0.45
$18.14+2.54%(+0.45)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
76Low Risk
Momentum
3Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
66.4%▲23.0pp
Revenue after COGS
Operating
5.6%▲67.9pp
After operating expenses
Net
-66.2%▲2.1pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-83.9
Price vs earnings
EV/EBITDA
3927.4
Enterprise value
FCF Yield
0.1%
Cash generation
Earnings Yield
-1.2%
Inverse of P/E
Capital Efficiency
-35
GoAI Quality ScorePoor
ROEReturn on Equity
-93.2%Weak
ROAReturn on Assets
-47.8%Weak
ROICReturn on Invested Capital
4.5%Fair
Financial Health
Current RatioHealthy
7.85
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-36.80x
Debt repayment capacity (<3x)
Income QualityWeak
-1.22
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $812.03M | $412.26M | $306.13M | $258.49M | $294.01M |
| Gross Profit | $539.17M | $178.78M | $89.31M | $80.02M | $184.16M |
| Gross Margin | 66.4% | 43.4% | 29.2% | 31.0% | 62.6% |
| Operating Income | $45.11M | -$257.12M | -$319.55M | -$315.76M | $139.09M |
| Net Income | -$537.96M | -$281.89M | -$341.42M | -$320.83M | $27.73M |
| Net Margin | -66.2% | -68.4% | -111.5% | -124.1% | 9.4% |
| EPS | -$1.90 | -$2.70 | -$1.82 | -$1.57 | $1.55 |
Average Price Target
$31.33▲ 72.7% Upside
Past 12 Months
12 Month Forecast
Based on 7 Wall Street analysts offering 12 month price targets for Caris Life Sciences, Inc., the average price target is $31.33, with a high forecast of $38.00 and a low forecast of $26.00. The average price target represents a 72.7% increase from the current price of $18.14.
Highest
$38.00
Average
$31.33
Lowest
$26.00
Rating Distribution
Strong Buy
0
0%
Buy
5
83%
Hold
1
17%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Evercore ISI Group● Maintain
Outperform
2026-02-27Baird● Maintain
Outperform
2026-02-27BTIG● Maintain
Buy
2026-02-27Canaccord Genuity● Maintain
Hold
2025-12-22Guggenheim● Maintain
Buy
2025-08-13Citigroup● Maintain
Buy
2025-08-13Evercore ISI Group● Maintain
Outperform
2025-08-13Earnings History & Surprises
BEAT RATE
67%
Last 3 quarters
AVG SURPRISE
+173.3%
EPS vs Estimate
BEATS / MISSES
2/1
Last 3 quarters
LATEST EPS
$0.28
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+477.0%
$0.28 vs $0.05
Q4 '25
+200.0%
$0.08 vs $-0.08
Q3 '25
-157.1%
$-0.54 vs $-0.21
No investor questions available.
Latest News
No news available